Related Experiment Video
Updated: Jun 16, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Triple therapy vs dual inhaler therapy for moderate-to-severe asthma: An updated systematic review and meta-analysis
Daniel G Rayner1, Layla Bakaa2, Flavia Hoyte3
1Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada; Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Background:
Long-acting muscarinic antagonists are typically added to inhaled corticosteroids (ICS) and long-acting β-agonists (LABA) for asthma management.
Objective:
To systematically synthesize the benefits and harms of triple therapy (ICS/LABA/long-acting muscarinic antagonists) compared with dual therapy (ICS/LABA) for asthma management across key subpopulations as part of developing linked American Academy of Allergy, Asthma, and Immunology/American College of Allergy, Asthma, and Immunology guidelines.
Methods:
We searched MEDLINE, EMBASE, the Cochrane Controlled Register of Trials, and the International Clinical Trials Registry Platform from January 1, 2020 to February 1, 2025, for randomized trials comparing inhaled triple therapy to dual therapy for asthma to update our previous systematic review. Paired reviewers independently screened citations, extracted data, and assessed the risk of bias. Random effects meta-analyses assessed asthma control (asthma control questionnaire-7; 0-6), asthma-related quality of life (asthma quality of life questionnaire; 1-7), prebronchodilator forced expiratory volume in 1 second, severe exacerbations, and serious adverse events. The Grading of Recommendations, Assessment, Development, and Evaluation approach informed the certainty of evidence. Open Science Framework Registration (https://osf.io/u8t4q/).
Results:
A total of 26 trials randomized 12,431 participants. Compared with dual therapy, triple therapy reduces severe exacerbations in patients at high risk for future exacerbation (relative risk 0.83, 95% CI 0.76-0.90; risk difference 5.3% fewer; high certainty), with trivial improvement in asthma control (mean difference [MD] -0.04, 95% CI -0.07 to 0.00, moderate certainty; lower better), quality of life (MD 0.05, 95% CI -0.03 to 0.14, moderate certainty; higher better), and prebronchodilator forced expiratory volume in 1 second (MD 0.07, 95% CI 0.05-0.09; high certainty), without increase in serious adverse events (moderate certainty). The effects were consistent across age, body mass index, and exacerbation history.
Conclusion:
In patients with moderate-to-severe asthma, triple therapy, compared with dual therapy, reduces severe exacerbations in patients at high risk for future exacerbation with minimal harm.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:23Inhaled Medications
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...